Advancing Cancer Immunotherapy through Engineering New PD-L1 Degraders: A Comprehensive Study from Small Molecules to PD-L1-Specific Peptide-Drug Conjugates

Zekun Zeng,Zhiwei Yang,Chenghao Li,Shujing Liu,Wei Wei,Ye Zhou,Simeng Wang,Mengjun Sui,Mengdan Li,Shumei Lin,Yangyang Cheng,Peng Hou
DOI: https://doi.org/10.1021/acs.jmedchem.4c01652
IF: 8.039
2024-10-19
Journal of Medicinal Chemistry
Abstract:Despite the considerable achievements of antibodies targeting PD-1/PD-L1 in cancer immunotherapy, limitations in antitumor immune response and pharmacokinetics hinder their clinical adoption. Small molecules toward PD-L1 degradation signifies an innovative avenue to modulate PD-1/PD-L1 axis. Herein, we unveil a comprehensive engineering involving the development of new PD-L1 degraders based on the berberine (BBR) and palmatine (PMT) bioactive frameworks and explore their translational potential...
chemistry, medicinal
What problem does this paper attempt to address?